American Urological Association's Annual Meeting (AUA) | Conference

Overall Survival With Lutetium 177 May Be Impacted by Subsequent Therapies, Prognostic Risk Groups in mCRPC
October 10, 2021

The CALGB prognostic risk group and subsequent life-prolonging therapies could potentially impact overall survival in patients with metastatic castration-resistant prostate cancer who are receiving lutetium 177.

UGN-101 Results in a Long-Lasting Response in Low-Grade Upper Tract Urothelial Carcinoma
September 26, 2021

Patients with low-grade upper tract urothelial carcinoma achieved a long period of durable response after undergoing treatment with UGN-101.

Yoga May Promote Antitumor Immune Responses and Boost Quality of Life in Prostate Cancer
September 25, 2021

Yoga not only yields improvements in physical, mental, and sexual wellbeing, but it may also result in reduced inflammation and antitumor responses in men with prostate cancer.

Response to Immunotherapy in Prostate Cancer Correlates With MSI-H/dMMR
September 18, 2021

An analysis of patients with prostate cancer treated with immune checkpoint blockade indicated that microsatellite instability and mismatch repair may be indicative of response.

Antitumor Activity Continues With Olaparib Plus Pembrolizumab Combo in mCRPC
September 15, 2021

Promising responses seen with the combination of pembrolizumab and olaparib in a cohort of patients with metastatic castration-resistant prostate cancer has led to the initiation of a phase 3 trial.

PROSPER: Enzalutamide Benefit in Nonmetastatic CRPC?
May 22, 2018

A new analysis of PROSPER, presented at AUA 2018, suggests enzalutamide plus ADT may be superior to ADT alone in nonmetastatic CRPC.